Bevacizumab (avastin) for corneal neovascularization--corneal light shield soaked application

To describe a case where topical bevacizumab (Avastin) was used in an attempt to reduce corneal neovascularization before corneal graft. Topical bevacizumab was applied through a corneal light shield for 20 minutes once a week for 11 weeks to the cornea. Corneal vascularization was not reduced. Topi...

Full description

Saved in:
Bibliographic Details
Published inCornea Vol. 28; no. 2; p. 246
Main Authors Mackenzie, Sarah E, Tucker, William R, Poole, Tom R G
Format Journal Article
LanguageEnglish
Published United States 01.02.2009
Subjects
Angiogenesis Inhibitors - administration & dosage
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal, Humanized
Bevacizumab
Corneal Neovascularization - complications
Corneal Neovascularization - drug therapy
Corneal Neovascularization - pathology
Corneal Transplantation
Drug Delivery Systems
Glaucoma - complications
Glaucoma - surgery
Glaucoma Drainage Implants
Graft Rejection - complications
Humans
Male
Middle Aged
Preoperative Care
Reoperation
Treatment Outcome
Online AccessGet more information

Cover

More Information
Summary:To describe a case where topical bevacizumab (Avastin) was used in an attempt to reduce corneal neovascularization before corneal graft. Topical bevacizumab was applied through a corneal light shield for 20 minutes once a week for 11 weeks to the cornea. Corneal vascularization was not reduced. Topical bevacizumab was not effective in this case at reducing corneal neovascularization.
ISSN:1536-4798
DOI:10.1097/ICO.0b013e3181861cc9